ORAL ETOPOSIDE IN COMBINATION WITH FARNESYLTRANSFERASE INHIBITOR R115777

口服依托泊苷与法呢基转移酶抑制剂 R115777 组合

• 批准号: 7604648
• 负责人: JUDITH KARP
• 金额: $ 0.87万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604648
• 关键词: Adult; Age; Complex; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic agent; Disease; Etoposide; Exhibits; Farnesyl Transferase Inhibitor; Funding; Genomics; Grant; Institution; Oral; Outcome; R115777 (Zarnestra); Research; Research Personnel; Resistance; Resources; Source; Toxin; United States National Institutes of Health; age group; chemotherapy; cytotoxic; genetic profiling; older patient; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The outcome and survival for adults age 70 and older with AML remains poor. Part of this poor response relates to the inability of very elderly patients (age > 75) to tolerate intensive chemotherapy [13-17]. More important, however, is the inherent resistance of these AMLs to the cytotoxic effects of traditional cytotoxic agents [14,17]. The AMLs that arise in the older age group often do so from an antecedent hematologic disorder (mainly MDS) that itself has evolve from a background of toxin exposures. These MDS/AMLS exhibit a complex genetic profile, likely a result of cumulative genomic damage .

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 70 岁及以上患有 AML 的成年人的预后和生存率仍然很差。这种不良反应的部分原因在于高龄患者（年龄 > 75 岁）无法耐受强化化疗 [13-17]。然而，更重要的是这些 AML 对传统细胞毒性药物的细胞毒性作用具有固有的抵抗力 [14,17]。老年组中出现的 AML 通常是由先前的血液系统疾病（主要是 MDS）引起的，而该疾病本身是由毒素暴露背景演变而来的。这些 MDS/AMLS 表现出复杂的遗传特征，可能是基因组损伤累积的结果。